Literature DB >> 11090243

Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases.

D Sánchez1, L Tucková, P Sebo, M Michalak, A Whelan, I Sterzl, L Jelínková, E Havrdová, M Imramovská, Z Benes, S Krupicková, H Tlaskalová-Hogenová.   

Abstract

Calreticulin (CRT), a high-affintiy calcium binding protein and chaperone, was recently identified as one of the targets of autoantibodies in coeliac disease. We evaluated the level of IgA and IgG antibodies to CRT in sera from patients with coeliac disease and various autoimmune diseases. The level of antibodies to gliadin (shown previously to cross-react with CTR), isolated enterocytes and tissue transglutaminase were determined for comparison. The mean level of IgA antibodies to CRT was significantly higher (P< 0.001) in sera from coeliac patients with active disease (139.9+/-11.2 AU/+/-SE) than in healthy controls (20.9+/-1.7 AU). In sera of patients with systemic lupus erythematosus (SLE), insulin dependent diabetes mellitus (IDDM), multiple sclerosis (MS) and autoimmune thyroiditis (AT) or inflammatory bowel disease (IBD) the mean level (25.8+/-3.7 to 38.1+/-5.6 AU) did not exceed the cut-off value. A low level of these antibodies, however, was detected in some sera of patients with MS and IBD. The level of IgG anti-CRT antibodies was increased in coeliac patients (mean 125.4+/-8.0 AU, P< 0.001) when compared to that in healthy controls (33.9+/-2.3 AU). The IgG anti-CRT antibodies were also detected in about 30% of SLE patients sera (54.1+/-3.6 AU, P< 0.001), but the mean level reached only half that detected in coeliac patients. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090243     DOI: 10.1006/jaut.2000.0452

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  18 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

Review 2.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

3.  The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics.

Authors:  Tara K Sigdel; Nathan Salomonis; Carrie D Nicora; Soyoung Ryu; Jintang He; Van Dinh; Daniel J Orton; Ronald J Moore; Szu-Chuan Hsieh; Hong Dai; Minh Thien-Vu; Wenzhong Xiao; Richard D Smith; Wei-Jun Qian; David G Camp; Minnie M Sarwal
Journal:  Mol Cell Proteomics       Date:  2013-12-12       Impact factor: 5.911

4.  Serological and clinical comparison of children and adults with anti-endomysial antibodies.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Nedeljko Radlovic; Ivana Davidovic; Ljiljana Sofronic; Milan Spuran; Marjan Micev; Milos M Nikolic
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

5.  Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.

Authors:  Dae Yong Kim; Bum Soo Park; Gwan Ui Hong; Byung Jae Lee; Jung Won Park; Soo Youl Kim; Jai Youl Ro
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.

Authors:  E V Staikou; J G Routsias; A A Makri; A Terzoglou; M Sakarellos-Daitsiotis; C Sakarellos; G Panayotou; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 7.  Triggers and drivers of autoimmunity: lessons from coeliac disease.

Authors:  Ludvig M Sollid; Bana Jabri
Journal:  Nat Rev Immunol       Date:  2013-03-15       Impact factor: 53.106

Review 8.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

9.  Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.

Authors:  D Sánchez; L Palová-Jelínková; J Felsberg; M Simsová; A Pekáriková; B Pecharová; I Swoboda; T Mothes; C J J Mulder; Z Benes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

10.  The serologic screening for celiac disease in the general population (blood donors) and in some high-risk groups of adults (patients with autoimmune diseases, osteoporosis and infertility) in the Czech republic.

Authors:  Z Vanciková; V Chlumecký; D Sokol; D Horáková; E Hamsíková; T Fucíková; I Janatková; Z Ulcová-Gallová; J Stĕpán; Z Límanová; M Dvorák; P Kocna; D Sánchez; L Tucková; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.